Chinese advisers push for tougher generics quality standards

China's political advisers are encouraging domestic generic drug development--but at the same time, they're also pushing for tougher quality standards. Thursday, a top advisory body suggested cutting some of the red tape associated with drugmaking. Doing so shouldn't come at the expense of quality, though, it cautioned. "Improving the quality of generic drugs concerns the sustainability of the health insurance system and matters to whether people can afford efficient drugs," it said in a statement seen by local news outlet Xinhua. More from FiercePharmaAsia

Suggested Articles

The future may be uncertain for AZ’s Imfinzi in first-line lung cancer, but its targeted med Tagrisso now boasts a green light in that setting.

Ultragenyx is back with another FDA nod, this time for Crysvita to treat X-linked hypophosphatemia in patients one year and older.

Roche got a two pieces of good Hemlibra news early this week—and what's good for Hemlibra must be good for Roche.